The therapy is intended for the treatment of non-operable critical limb ischemia. The therapy is currently in clinical trials. “We experienced an 82 percent major amputation free rate in the intent-to-treat patients, and significant reductions in hard clinical endpoints including VAS pain scores and a meaningful improvement in the six minute walk test,” said Ken Harris, president of Cesca Therapeutics.
Cesca Therapeutics focuses on the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine.
More articles on devices:
Medtronic keeps getting bigger — acquires Sapiens Steering Brain Stimulation for $200M
Amedica names Dr. B. Sonny Bal chairman of the board
Spine Pain Management names David Spencer CIO
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
